Search | Clinical Trials Finder

Conditions: Premature Ovarian Failure
Interventions: Dehydroepiandrosterone, Placebo; Dietary Supplement
Lead sponsor: David H. Barad; Other
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Premature Ovarian Failure
Interventions: Estradiol/Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Ovarian Function, Preservation of Ovarian Function
Interventions: GnRH antagonist; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years to 21 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: AZD 1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more

Conditions: Healthy, Osteoporosis, Premature Ovarian Failure
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 32 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Insufficiency
Interventions: Group reading and discussion; Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Early Menopause, Cancer, Premature Menopause, Surgical Menopause
Interventions: Nurse Navigator Intervention, Education Control; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions: lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF; Procedure · Device · Drug
Lead sponsor: Black Tie Medical, Inc.; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Colchester, Vermont

Conditions: Primary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 25 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Planned RRSO
Interventions: Lisdexamfetamine, Estradiol, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 48 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Effects of Chemotherapy
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 11 Years to 50 Years · Female only
Enrollment: 391 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2020
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Radnor, Pennsylvania

Conditions: Cancer, Risk of Premature Ovarian Failure, Fertility Preservation
Interventions: surgery to remove ovaries or high dose chemotherapy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cognitive Impairments, RRSO
Interventions: lisdexamfetamine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Goserelin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 46 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cognitive Impairment, RRSO
Interventions: Lisdexamfetamine, Placebo oral capsule; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 35 Years to 58 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Turner Syndrome, Primary Ovarian Insufficiency
Interventions: Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 12 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer, Ovarian Insufficiency, Ovarian Failure
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 2
States / cities: La Jolla, California • Philadelphia, Pennsylvania

Conditions: Diminished Ovarian Reserve, Ovarian Failure
Interventions: A-PRP; Procedure
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 52 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Autoimmune Disease, Infertility, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gestational Diabetes Mellitus (GDM), Pregnancy
Interventions: Fermented Poi; Other
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Honolulu, Hawaii • Waimanalo, Hawaii

Conditions: Primary Ovarian Insufficiency, Premature Menopause
Interventions: A-PRP; Procedure
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions: Nonmyeloablative Allogeneic Transplant; Procedure
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

Familial Investigations of Childhood Cancer Predisposition

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Hormone Replacement in Young Women With Premature Ovarian Failure

Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency

X-Chromosome Inactivation Status and Premature Ovarian Failure

Improving Outcomes in Early Menopause After Cancer

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

Assessing Fertility Potential in Female Cancer Survivors

Cryopreservation of Ovarian Tissue

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

IMProving Executive Function Study

Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

Study of PRP in Women With Evidence of Diminished Ovarian Reserve

Steroid Therapy in Autoimmune Premature Ovarian Failure

Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk

Injections of Autologous PRP in Women With Primary Ovarian Insufficiency

Nonmyeloablative Allogeneic Transplant